Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan
With its new drug application for the pioneering CAR-T drug KTE-C19 in the final weeks from being completed and shipped to regulators in search of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
